Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Online CME Information
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wozniak, D. J.
Right arrow Articles by Keyser, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wozniak, D. J.
Right arrow Articles by Keyser, R.
(Chest. 2004;125:62S-69S.)
© 2004 American College of Chest Physicians

Effects of Subinhibitory Concentrations of Macrolide Antibiotics on Pseudomonas aeruginosa*

Daniel J. Wozniak, PhD and Rebecca Keyser, BS

* From the Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC.

Correspondence to: Daniel J. Wozniak, PhD, Department of Microbiology and Immunology, 5138 Gray Building, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157; e-mail: dwozniak{at}wfubmc.edu

Biofilm-forming bacteria such as Staphylococcus, Haemophilus, and Pseudomonas species resist phagocytosis by host immune cells and the actions of antimicrobial agents. In susceptible individuals, such as patients with cystic fibrosis (CF) or diffuse panbronchiolitis (DPB), strains of Pseudomonas aeruginosa produce a number of virulence determinants that permit colonization and infection of the respiratory tract. P aeruginosa strains isolated from CF and DPB patients typically have a mucoid colony morphology. This is due to the overproduction of alginate, an exopolysaccharide capsule that is composed of D-mannuronic and L-guluronic acids. In addition, the P aeruginosa type IV pilus mediates cell surface translocation by a process known as twitching motility. Both alginate production and twitching motility contribute to the virulence of P aeruginosa, as does the formation of biofilms. Biofilms bind cells and organic and inorganic materials to each other, and to a variety of substrata. Their tightly formed structure reduces antimicrobial activity, promotes bacterial adhesion to lung epithelia, and prevents bacterial dehydration. Prior work has suggested that macrolides have therapeutic value in patients with DPB and CF. We hypothesized that the improved clinical status of these patients was due, in part, to macrolides inhibiting the production of P aeruginosa virulence determinants. Traditionally, macrolides have not been considered to exhibit antipseudomonal activity, as their mean inhibitory concentration (MIC) values for clinical and environmental strains of the microbe range from 50 to 550 µg/mL. In this study, we found that sub-MIC levels of clarithromycin substantially inhibited twitching motility. In addition, the incubation of biofilm-grown P aeruginosa with clarithromycin altered the structure and architecture of the biofilm. Investigating the potential nonribosomal effects of macrolides on opportunistic pathogens such as P aeruginosa and elucidating the molecular mechanisms that underlie the inhibition of twitching motility may lead to more effective treatments of pulmonary infections in patients with CF and DPB.

Key Words: adenosine triphosphate-binding cassette • alginate • asialoGM1 • biofilms • cystic fibrosis transmembrane conductance regulator • diffuse panbronchiolitis • nucleotide-binding domain • Pseudomonas aeruginosa • twitching motility • type IV pili




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
A. M. Rios, M. Fonseca-Aten, A. Mejias, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr., O. Ramilo, and R. D. Hardy
Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3970 - 3973.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince
Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients
Chest, August 1, 2005; 128(2): 912 - 919.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
S C Bell, S L Senini, and J G McCormack
Macrolides in cystic fibrosis
Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98.
[Abstract] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Chen, G. W. Sun, K. L. Chua, and Y.-H. Gan
Modified Virulence of Antibiotic-Induced Burkholderia pseudomallei Filaments
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1002 - 1009.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Pallasch, D. L. Brown, L. M. Golub, and J. G. Thomas
Subantimicrobial Doses of Tetracycline
Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): e163 - e163.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.